Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months

Immune Thrombocytopenia Clinical Trial

Official title:

A Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With Immune Thrombocytopenia (ITP) of ≤6 Months Duration

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05046327
• Other study ID #: AVA-ITP-306
• Status: Withdrawn
• Phase: Phase 3
• Start date: October 14, 2021
• Est. completion date: February 19, 2025

Study information

• Verified date: October 2021
• Source: Dova Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of avatrombopag in subjects with a confirmed diagnosis of primary ITP (≤6 months duration) over 26 weeks of treatment, and also evaluate the incidence of ITP remission.

Description:

This phase 3b, multi-center, open-label study will enroll approximately 75 adult subjects with a confirmed diagnoses of primary ITP (≤6 months duration) who have had a previous response to a first line treatment. The study will consist of a 26-week treatment period to evaluate the safety and efficacy of avatrombopag. Subjects with platelet counts ≥50×10⁹/L at Week 26 may enter a dose-tapering period in which the dose of avatrombopag will be decreased for up to 16 weeks until avatrombopag treatment is discontinued and the platelet count is maintained ≥50×10⁹/L. Once avatrombopag treatment has been discontinued, the subjects will enter a remission evaluation period of up to 24 weeks to evaluate whether they have entered a state of remission.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 19, 2025
• Est. primary completion date: April 6, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subjects =18 years of age at Screening.

2. Subject must be able to provide informed consent.

3. Subject has a confirmed diagnosis of primary ITP according to the International Consensus Report on the Investigation and Management of Primary ITP within the previous 6 months prior to Visit 1 and has had a previous response to a first line treatment (corticosteroids, IVIg, or anti-D), in the opinion of the Investigator.

4. Subject has at least one platelet count <30×10?/L at any time during the screening period or at the Baseline visit.

5. Females of childbearing potential must have a negative pregnancy test at Screening and Baseline.

6. Female subjects of childbearing potential who are sexually active and male subjects who are sexually active must agree to use effective methods of contraception.

7. Subject is willing and able to comply with all aspects of the protocol.

Exclusion Criteria:

1. Thrombocytopenia due to a known condition other than primary ITP (e.g., systemic lupus erythematosus, H. pylori infection, splenomegaly, chronic liver disease).

2. Any history of arterial or venous thrombosis, including partial or complete thrombosis (history of superficial thrombophlebitis is not exclusionary).

3. Subjects with known inherited thrombocytopenia (e.g., MYH-9 disorders).

4. History of myelodysplastic syndrome (MDS) or other hematologic malignancies.

5. Current history of significant cardiac arrhythmias or decompensated congestive heart failure.

6. History of hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV).

7. Previous use of eltrombopag, romiplostim, recombinant human TPO or other platelet-producing agents.

8. Surgical resection of the spleen.

9. Previous use of mycophenolate mofetil (MMF), rituximab (or other B-cell lymphocyte depleting agents), mercaptopurine (6-MP) or alkylating agents.

10. Concurrent malignant disease, other than non-melanoma skin cancer or cervical cancer in-situ.

11. Known allergy to avatrombopag or any of its excipients.

12. Subject is unable to take oral medication or has a malabsorption syndrome or any other uncontrolled gastrointestinal condition.

13. Enrollment in another clinical study with any investigational drug or device within 30 days of Day 1/Visit 2 (or 5 half-lives, whichever is longer); however, participation in observational studies is permitted.

14. Any clinically relevant abnormality which makes the subject unsuitable for participation in the study, in the opinion of the Investigator.

15. Considered unable or unwilling to comply with the study protocol requirements.

Related Conditions & MeSH terms

• Immune Thrombocytopenia
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• Avatrombopag 20 mg Oral Tablet
Avatrombopag administered at a frequency to maintain a target platelet count between =50 and =150×10?/L

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Dova Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative Number of Weeks of Platelet Response	Cumulative number of weeks of platelet response in which the platelet count is =50×10?/L during 6 months of treatment in the absence of rescue therapy.	6 Months of Active Treatment
Secondary	Durable Platelet Response	Durable platelet response as defined by the incidence of subjects who have at least 6 out of 8 weekly platelet counts =50×10?/L during the last 8 weeks of treatment.	8 Weeks of Treatment
Secondary	Incidence of ITP remission	Incidence of ITP remission as defined by platelet count =50×10?/L for 24 consecutive weeks with no ITP treatments (concomitant or rescue).	24 Consecutive Weeks
Secondary	Incidence of subjects achieving a platelet count response	Incidence of subjects achieving a platelet count response (=50×10?/L) during the active treatment period of the study.	6 Months of Active Treatment